The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Giovanni Lucignani

Department of Biomedical Sciences and Technologies

University of Milan

Department of Diagnostic Services

San Paolo Hospital

Italy

[email]@unimi.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Biomedical Sciences and Technologies, University of Milan, Department of Diagnostic Services, San Paolo Hospital, Italy. 2009 - 2010
  • Institute of Radiological Sciences, University of Milan, San Paolo Hospital, Milan, Italy. 2006 - 2009
  • Institute of Radiological Sciences, University of Milan and Unit of Molecular Imaging, Division of Radiation Therapy, European Institute of Oncology, Italy. 2006
  • Istituto Europeo di Oncologia, Radiotherapy Department, Università degli Studi di Milano, via Ripamonti 435, Italy. 2004
  • Università di Milano, Ospedale L. Sacco, Italy. 2002

References

  1. Radiation burden in myocardial imaging: an old concern in the new age of hi-tech, hybrid imaging. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2010) [Pubmed]
  2. Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. Lucignani, G., Perneczky, R. Eur. J. Nucl. Med. Mol. Imaging (2010) [Pubmed]
  3. Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours. Lucignani, G., Larson, S.M. Eur. J. Nucl. Med. Mol. Imaging (2010) [Pubmed]
  4. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Lucignani, G., Orunesu, E., Cesari, M., Marzo, K., Pacei, M., Bechi, G., Gori, A., Gaito, S., Clerici, M., Chiti, A. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  5. Beyond haematuria in uro oncology: imaging biomarkers lag behind needs. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  6. Respiratory and cardiac motion correction with 4D PET imaging: shooting at moving targets. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  7. Diagnosing pulmonary embolism: clinical problem or methodological issue?. Lucignani, G., Pistolesi, M. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  8. SUV and segmentation: pressing challenges in tumour assessment and treatment. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  9. Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  10. Amyloid imaging with PET: methodological issues and correlative studies. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  11. Clinical applications of PET amyloid imaging: an update. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  12. Metaiodobenzylguanidine (mIBG) molecular imaging in implantable cardioverter defibrillator (ICD) therapy planning: a health technology assessment issue. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  13. Monitoring cancer therapy with PET: probably effective, but more research is needed. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  14. Advances in quantitative assessment of myocardial blood flow and coronary reserve. Lucignani, G., Cuocolo, A. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  15. Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy. Lucignani, G., Bombardieri, E. Eur. J. Nucl. Med. Mol. Imaging (2009) [Pubmed]
  16. Clinical use of dopamine transporter imaging in movement disorders: benefits of appropriate use. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  17. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  18. Facts and figures on CAD assessment with SPECT and PET-CT. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  19. Labeling peptides with PET radiometals: Vulcan's forge. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  20. Cardiac sympathetic denervation imaging in movement disorders and dementias. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  21. PET imaging with hypoxia tracers: a must in radiation therapy. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  22. Advances in prostate cancer imaging techniques and strategies. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  23. The power of synergy in the mediastinal staging of lung cancer. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  24. PET-MRI synergy in molecular, functional and anatomical cancer imaging. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  25. Oesophageal cancer: can imaging improve its assessment?. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  26. FDG-PET in gynaecological cancers: recent observations. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  27. Hi-tech systems for in-vivo image-guided preclinical radiobiology. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2008) [Pubmed]
  28. Imaging atherosclerosis in the vulnerable patient. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  29. Non-standard PET radionuclides: time to get ready for new clinical PET strategies. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  30. Molecular imaging is indispensable for the development of stem cell-based myocardial regenerative therapy. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  31. How early? ASAP: molecular and functional imaging!. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  32. The emergence of MRI and MSCT cardiac imaging: nuclear cardiology is not the only actor on the stage. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  33. Clinical neuroimaging: a matter of biophysics and logistics. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  34. Bone and marrow imaging: do we know what we see and do we see what we want to know?. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  35. Hints on new applications of emission tomography and magnetic resonance in neuro-oncology. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  36. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  37. The many roads to infection imaging. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  38. Imaging biomarkers: from research to patient care--a shift in view. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  39. Rubor, calor, tumor, dolor, functio laesa... or molecular imaging. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2007) [Pubmed]
  40. Imaging in cancer therapy and drug development. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  41. The immune system and cancer: the evolving role of molecular imaging and molecular targeted therapy. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  42. PET/CT cardiology: an area whose boundaries are still out of sight. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  43. The neuroimaging approach to the assessment of mild cognitive impairment. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  44. Pivotal role of nanotechnologies and biotechnologies for molecular imaging and therapy. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  45. Time-of-flight PET and PET/MRI: recurrent dreams or actual realities?. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  46. Molecular imaging of cell-mediated cancer immunotherapy. Lucignani, G., Ottobrini, L., Martelli, C., Rescigno, M., Clerici, M. Trends Biotechnol. (2006) [Pubmed]
  47. Aptamers and in-beam PET for advanced diagnosis and therapy optimisation. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  48. Sentinel lymph node biopsy: vision, multicentre trials, professional and technological synergy. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  49. Customized imaging for children and obese people: key issues and strategies. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  50. Neuroimaging: a story of physicians and basic scientists. Lucignani, G., Bastianello, S. Funct. Neurol. (2006) [Pubmed]
  51. Data acquisition and analysis: the strength of methodology in nuclear medicine and molecular imaging. Lucignani, G. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  52. GABA A receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil. Lucignani, G., Panzacchi, A., Bosio, L., Moresco, R.M., Ravasi, L., Coppa, I., Chiumello, G., Frey, K., Koeppe, R., Fazio, F. Neuroimage (2004) [Pubmed]
  53. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders. Lucignani, G., Gobbo, C., Moresco, R.M., Antonini, A., Panzacchi, A., Bonaldi, L., Carpinelli, A., Caraceni, T., Fazio, F. Nucl. Med. Commun (2002) [Pubmed]
 
WikiGenes - Universities